ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2511

Longitudinal Observation of Disease Activity and Treatment of Rheumatoid Arthritis Who Developed Methotrexate-Associated Lymphoproliferative Disorders

Atsumu Osada1, Koji Kobayashi2, Yuji Yoshioka3, Haruko Ideguchi3 and Shohei Nagaoka3, 1Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 2Yokohama City University Medical Center, Yokohama, Japan, 3Yokohama Minami Kyosai Hospital, Yokohama, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lymph node and methotrexate (MTX)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Methotrexate-associated lymphoproliferative disorder(MTX-LPD) is rare but one of important complications in treatment of rheumatoid arthritis (RA). There are few reports about disease activity and optimal therapy of RA with MTX-LPD.

Methods:

We retrospectively analyzed background of patients, histology of LPD, treatment and disease activity of RA in 15 patients with MTX-LPD in our hospital between 2008 and 2014.

Results:

Our cases included 4 males and 11 females, and the median age of MTX-LPD onset was 70 years old (52-81). Average dose and period of MTX administration were 8.8 mg /week (4-16), 8.7 years (2.2-19.8), and 3681 mg in total (1372 -9485). Mean DAS28 (CRP) at MTX-LPD diagnosis was 2.00 (1.17-3.18). Extranodal lesions were observed in 8 cases. Three of 15 patients were diagnosed as Hodgikin lymphoma (HL), 2 as diffuse large B-cell lymphoma (DLBCL), 1 as Follicular lymphoma (FL), 1 as peripheral T-cell lymphoma (PTCL), 1 as Angioimmunoblastic T-cell lymphoma (AILT).

Lymphoproliferative lesions were improved spontaneously by discontinuation of MTX in 8 cases. Six of them showed relapse of RA in 3 to 65 months after MTX cessation, and Abatacept (ABT), administered in four cases, was effective without recurrence of LPD. Chemotherapy (CTx) was required in seven patients. Flare of arthritis, seen less common in CTx group, occurred in two cases in 18 and 36 months after CTx was finished. The propotion of patients associated with Sjögren’s syndrome (SS) was significantly larger in CTx group (57 % v.s. 0 %, p=0.026).

Conclusion:

It is suggested that RA flare is common after MTX-LPD and ABT can be safe and effective treatment in RA relapse. Absense of SS was associated with spontaneous remission of MTX-LPD.


Disclosure: A. Osada, None; K. Kobayashi, None; Y. Yoshioka, None; H. Ideguchi, None; S. Nagaoka, None.

To cite this abstract in AMA style:

Osada A, Kobayashi K, Yoshioka Y, Ideguchi H, Nagaoka S. Longitudinal Observation of Disease Activity and Treatment of Rheumatoid Arthritis Who Developed Methotrexate-Associated Lymphoproliferative Disorders [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/longitudinal-observation-of-disease-activity-and-treatment-of-rheumatoid-arthritis-who-developed-methotrexate-associated-lymphoproliferative-disorders/. Accessed December 12, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-observation-of-disease-activity-and-treatment-of-rheumatoid-arthritis-who-developed-methotrexate-associated-lymphoproliferative-disorders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.